From Medscape Diabetes & Endocrinology

ENDO 2017: The Endocrine Society Annual Meeting

April 01 - 04, 2017; Orlando, FL

April 01 - 04, 2017 Orlando, FL

ENDO Early Use of Triple Drug Cocktail Improves Ovulation in PCOS A treatment regimen combining two insulin sensitizers with an antiandrogenic agent may improve ovulation rates and metabolic parameters in girls with polycystic ovary syndrome before they were sexually active.
Medscape Medical News, April 11, 2017
ENDO 'Bioidentical' Oral Alternative to Compound Hormones on Horizon New oral fixed-dose combinations of 17-β estradiol and natural progesterone are being developed that, if approved, will offer a regulated alternative to compounded hormonal therapy for menopause symptoms.
Medscape Medical News, April 10, 2017
ENDO Abaloparatide Best in 'Really High-Risk' Osteoporosis Patients As anticipated US approval for a new anabolic agent, abaloparatide, for osteoporosis is delayed by 3 months, one expert discussed how he thinks the agent will best fit into the armamentarium.
Medscape Medical News, April 6, 2017

New Diabetes Drugs and the Cost, Benefit of Treatment With so many choices emerging to treat type 2 diabetes, experts debated the advantages and risks of conventional and cutting-edge options at ENDO 2017 and had some key takeaways to improve care.